Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-1 mimic is a synthetic, double-stranded RNA oligonucleotide designed to emulate the biological activity of the endogenous microRNA miR-1. In various cancers, including high-grade muscle-invasive bladder cancer, miR-1 is frequently downregulated and functions as a tumor suppressor. The miR-1 mimic acts by binding to the 3' untranslated region (UTR) of target mRNAs, most notably those encoding components of the ERK MAPK signaling pathway. This binding leads to translational repression or mRNA degradation, thereby reducing the protein levels of ERK MAPK and inhibiting tumor cell proliferation and survival. While primarily used as a research tool to study gene regulation and potential therapeutic pathways, miR-1 mimics represent a class of RNA-based therapeutics aimed at restoring lost tumor-suppressive functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-1 mimic.